Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
Francesco Gelsomino(Azienda USL di Bologna), Andrea Ardizzoni(Azienda Ospedaliero-Universitaria Careggi), Saverio Cinieri(Ospedale A. Perrino), Lorenzo Tofani(University of Florence), Stefano Brocchi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Fausto Barbieri(University of Modena and Reggio Emilia), Ida Colantonio(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Angelo Delmonte(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Luigi Cavanna(University of Pavia), Francesca Sperandi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Giuseppe Lamberti(Dana-Farber Cancer Institute), Luca Boni(Ospedale Policlinico San Martino), Claudio Dazzi(Azienda Ospedaliero-Universitaria Careggi), Lucia Longo(Azienda Unita' Sanitaria Locale Di Modena), Marcello Tiseo(University of Parma), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 0
Related Papers
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
|British Journal of Cancer|2019|1.3k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k